Key Takeaways TEM debuts xM for TRM, a liquid biopsy assay to monitor response to ICI therapy in solid tumors.Tempus AI's xM uses ctDNA and a multi-parametric algorithm to assess molecular response in cancer patients.TEM expands its precision oncology tools as demand for ICI therapies rises in advanced cancers.Tempus AI, Inc. (TEM) recently introduced xM for treatment response monitoring (TRM), a liquid biopsy assay. It is designed to detect molecular response to immune-checkpoint inhibitor (ICI) therapy in ...